The US Lipid Nanoparticles Market was valued at $53.01 Million in 2024 and projected to reach to $69.79 Million by 2029, representing a compound annual growth rate of 5.7%. The US lipid nanoparticles market is positioned for sustained growth as mRNA therapeutics transition from pandemic response to broader therapeutic applications.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US lipid nanoparticles market is valued at $53.01 million in 2024, with a projected CAGR of 5.7% through 2029, reaching $69.79 million by forecast end.
US pharmaceutical companies are rapidly expanding mRNA-based drug pipelines, leveraging lipid nanoparticle delivery systems for oncology, infectious diseases, and personalized medicine applications.
The success of Pfizer-BioNTech and Moderna COVID-19 vaccines has established lipid nanoparticles as a proven platform technology, driving continued investment and clinical development in the US market.
The US maintains a dominant position in lipid nanoparticle research and development, with leading biotech hubs in California, Massachusetts, and New York driving innovation and commercialization.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | FORMULATION DEVELOPMENT SERVICES (Service Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.2% from 2024 to 2029 |
| Largest Segment | MRNA (Molecule Type) |
| Market Size Base Year (Billions) | ~USD 0.27 (2024) |
| Revenue Forecast (Billions) | ~USD 0.35 (2029) |
| Segments Covered | Product, Lnp Type, Molecule Type, Application, Type, End User, Service Type |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 22.1 | 17.3 | 17.7 | 18.3 | 18.9 | 19.6 | 20.4 | 21.2 | 3.7 |
| CDMOS | 34.4 | 27.4 | 28.5 | 29.9 | 31.4 | 33.2 | 35.1 | 37.2 | 5.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 40.2 | 32.3 | 33.8 | 35.7 | 37.9 | 40.3 | 43 | 46 | 6.3 |
| TOTAL | 96.7 | 77 | 80.1 | 83.9 | 88.2 | 93.1 | 98.5 | 104.4 | 5.4 |
The US lipid nanoparticles market was valued at $53.01 million in 2024 and is expected to grow to $69.79 million by 2029.
The US lipid nanoparticles market is projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2029.
The US market is driven by increased adoption of mRNA-based therapeutics, vaccine development, clinical pipeline expansion, and growing applications in oncology and immunotherapy.
The US market is experiencing growth in mRNA vaccines, oncology treatments, immunotherapy applications, and rare disease therapeutics utilizing lipid nanoparticle platforms.
The US represents a significant portion of the global market, with a 5.7% CAGR compared to the global rate of 5.2%, reflecting the US's leadership in pharmaceutical innovation and development.
This research study was conducted with analysis of both secondary sources and primary research inputs. Secondary sources involved key suppliers & customer filings, investor documents, clinical trial directories, industry associations, among others to collect information for the analysis of the global lipid nanoparticles market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key suppliers and customers, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the lipid nanoparticles market. The secondary sources used for this study include United States Food and Drug Administration (US FDA), National Cancer Institute (NCI), National Institutes of Health (NIH), Organization for Economic Co-operation and Development (OECD), Centers for Medicare and Medicaid Services (CMS), International Monetary Fund (IMF), German Federal Ministry of Education and Research (BMBF), UK Research and Innovation (UKRI), GLOBOCAN, Indian Council of Medical Research (ICMR), Korea Advanced Institute of Science and Technology (KAIST), Korea Drug Development Fund (KDDF), Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS), Association of Southeast Asian Nations (ASEAN), International Agency for Research on Cancer (IARC), World Economic Situation and Prospects (WESP), research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global lipid nanoparticles market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the lipid nanoparticles market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:


To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
lipid nanoparticles (LNPs) are tiny particles, typically measuring between 20 to 200 nanometers, made from various lipids. They are designed to encapsulate and deliver therapeutic agents, such as nucleic acids (mRNA, siRNA), small Molecule Types, and proteins, to specific cells or tissues. LNPs are composed of a mix of lipids, including phospholipids, cholesterol, and ionizable lipids, which self-assemble to form structures that protect and transport the therapeutic payload.
1 Micro markets are the further segments and subsegments of the lipid nanoparticles market included in the report
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Lipid Nanoparticles Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report